Callan Family Office LLC Invests $718,000 in HealthEquity, Inc. $HQY

Callan Family Office LLC acquired a new stake in HealthEquity, Inc. (NASDAQ:HQY) during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 7,954 shares of the company’s stock, valued at approximately $718,000.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the stock. Acumen Wealth Advisors LLC acquired a new stake in HealthEquity in the 4th quarter valued at about $27,000. Aster Capital Management DIFC Ltd purchased a new position in shares of HealthEquity in the 4th quarter valued at about $28,000. Caitong International Asset Management Co. Ltd grew its position in shares of HealthEquity by 1,723.5% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 310 shares of the company’s stock worth $28,000 after buying an additional 293 shares in the last quarter. Leonteq Securities AG grew its position in shares of HealthEquity by 159.9% during the first quarter. Leonteq Securities AG now owns 382 shares of the company’s stock worth $32,000 after buying an additional 235 shares in the last quarter. Finally, Silvant Capital Management LLC purchased a new stake in shares of HealthEquity during the second quarter worth approximately $35,000. 99.55% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of brokerages recently issued reports on HQY. Royal Bank Of Canada lifted their price target on shares of HealthEquity from $100.00 to $108.00 and gave the stock an “outperform” rating in a research note on Wednesday, June 3rd. BTIG Research raised their price objective on shares of HealthEquity from $110.00 to $115.00 and gave the company a “buy” rating in a report on Friday, July 24th. KeyCorp reaffirmed an “overweight” rating on shares of HealthEquity in a research report on Tuesday, May 26th. Citizens Jmp boosted their target price on shares of HealthEquity from $110.00 to $111.00 and gave the stock a “market outperform” rating in a research note on Monday, June 1st. Finally, Wall Street Zen upgraded shares of HealthEquity from a “hold” rating to a “buy” rating in a research note on Saturday. Eleven research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $110.93.

HealthEquity Stock Performance

Shares of HQY opened at $105.39 on Wednesday. The company has a market capitalization of $8.81 billion, a price-to-earnings ratio of 39.47, a price-to-earnings-growth ratio of 1.77 and a beta of 0.21. HealthEquity, Inc. has a 52-week low of $72.76 and a 52-week high of $107.62. The company has a quick ratio of 3.44, a current ratio of 3.44 and a debt-to-equity ratio of 0.46. The stock has a 50 day moving average price of $97.41 and a 200 day moving average price of $87.53.

HealthEquity (NASDAQ:HQY) last released its quarterly earnings data on Thursday, May 28th. The company reported $1.24 earnings per share for the quarter, topping analysts’ consensus estimates of $1.11 by $0.13. The company had revenue of $354.64 million for the quarter, compared to analysts’ expectations of $352.02 million. HealthEquity had a net margin of 17.25% and a return on equity of 14.75%. The company’s revenue was up 7.2% on a year-over-year basis. HealthEquity has set its FY 2027 guidance at 2.880-2.950 EPS. Research analysts predict that HealthEquity, Inc. will post 3.92 EPS for the current fiscal year.

Insider Buying and Selling

In other HealthEquity news, EVP Michael Henry Fiore sold 2,354 shares of the firm’s stock in a transaction dated Friday, July 10th. The stock was sold at an average price of $95.00, for a total transaction of $223,630.00. Following the transaction, the executive vice president owned 52,244 shares of the company’s stock, valued at approximately $4,963,180. This trade represents a 4.31% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Gayle Furgurson Wellborn sold 2,439 shares of HealthEquity stock in a transaction dated Thursday, May 28th. The stock was sold at an average price of $90.00, for a total value of $219,510.00. Following the sale, the director owned 19,733 shares in the company, valued at $1,775,970. This trade represents a 11.00% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 17,905 shares of company stock worth $1,651,280 in the last ninety days. 1.60% of the stock is owned by corporate insiders.

HealthEquity Company Profile

HealthEquity, Inc (NASDAQ: HQY) is a leading administrator of consumer-directed health accounts and related benefit solutions in the United States. Founded in 2002 and headquartered in Draper, Utah, the company specializes in health savings accounts (HSAs) and offers complementary services such as flexible spending accounts (FSAs), health reimbursement arrangements (HRAs), COBRA administration and commuter benefits. Through its technology-driven platform, HealthEquity enables employers, health plans and individuals to streamline account management, improve cost transparency and encourage more informed healthcare spending.

Serving millions of members across all 50 states, HealthEquity leverages an open-architecture ecosystem that integrates with health plans, payroll providers and financial institutions.